Shattuck Labs, Inc. (STTK) shareholders
STTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.81−0.24 (-4.75%)
Close on Nov 12, 2026Market cap $482.75MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
83.5%
84M of 100M shares
Institutional holders
100
37 new, 20 sold out
Net institutional buying
28M
In Q2 2026
Insider trades, 12 months
1 buys · 6 sales
Net sold $341.85K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13,432,540 | 15.30% | 13G (passive) amendment | Jun 30, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (9.90%), Redmile Biopharma Investments II, L.P. (8.10%) | 10,019,421 | 9.90% | 13D (active) amendment | Jul 15, 2026 |
| Orbimed Advisors LLC Joint filing with OrbiMed Capital GP IX LLC (8.33%) | 9,021,127 | 9.99% | 13D (active) amendment | Jun 11, 2026 |
| Prosight Management, LP Joint filing with Prosight Partners, LLC (9.90%), W. Lawrence Hawkins (9.90%) | 6,543,240 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Jeremy C. Green Joint filing with Redmile Group, LLC (11.80%), Redmile Biopharma Investments II, L.P. (7.00%) | 5,652,660 | 11.80% | 13D (active) amendment | Aug 4, 2025 |
| BlackRock, Inc. | 5,339,458 | 5.30% | 13G (passive) | Sep 30, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (5.17%), David Kroin (5.17%) | 5,000,033 | 5.17% | 13G (passive) | Jun 10, 2026 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (9.79%), Robert Atchinson (9.79%) | 4,675,000 | 9.79% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of STTK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13,432,540 | 13.38% | $93.22M | +3,566,982 | 0.06% |
| Adage Capital Partners Gp, L.L.C. | 8,122,179 | 8.09% | $56.37M | +3,477,222 | 0.08% |
| Redmile Group, LLC | 6,892,033 | 6.87% | $47.83M | +1,352,309 | 3.21% |
| Orbimed Advisors LLC | 6,306,127 | 6.28% | $43.76M | – | 0.81% |
| Prosight Management, LP | 5,957,877 | 5.94% | $41.35M | +953,438 | 7.12% |
| BlackRock, Inc. | 3,935,810 | 3.92% | $27.31M | +3,425,004 | 0.00% |
| Frazier Life Sciences Management, L.P. | 3,750,000 | 3.74% | $26.03M | New | 0.57% |
| NEXTBio Capital Management LP | 3,727,348 | 3.71% | $25.87M | +577,441 | 11.90% |
| Deep Track Capital, LP | 3,706,734 | 3.69% | $25.72M | New | 0.37% |
| Vanguard Capital Management LLC | 3,207,865 | 3.20% | $22.26M | +930,689 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,641,076 | 2.63% | $18.33M | +858,288 | 0.00% |
| Pinnacle Associates Ltd | 1,871,442 | 1.86% | $12.99M | +503,219 | 0.14% |
| Wellington Management Group Llp | 1,767,938 | 1.76% | $12.27M | New | 0.00% |
| Geode Capital Management, LLC | 1,584,756 | 1.58% | $11.00M | +939,051 | 0.00% |
| Clark Estates Inc/Ny | 1,430,167 | 1.42% | $9.93M | −45,481 | 2.29% |
| abrdn plc | 1,405,851 | 1.40% | $9.76M | +246,530 | 0.01% |
| Point72 Asset Management, L.P. | 1,170,732 | 1.17% | $8.12M | +139,683 | 0.01% |
| 683 Capital Management, LLC | 1,157,216 | 1.15% | $8.03M | +357,216 | 0.39% |
| State Street Corp | 1,026,394 | 1.02% | $7.12M | +762,626 | 0.00% |
| Boxer Capital Management, LLC | 1,000,000 | 1.00% | $6.94M | New | 0.52% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 100 | 84M | 83.5% | 37 / 36 | 15 / 20 | 33M | 5M |
| Q1 2026 | 84 | 56M | 55.9% | 24 / 33 | 14 / 4 | 20M | 4M |
| Q4 2025 | 65 | 43M | 42.4% | 17 / 17 | 14 / 4 | 11M | 4M |
| Q3 2025 | 56 | 36M | 36.3% | 14 / 11 | 23 / 18 | 11M | 3M |
| Q2 2025 | 61 | 29M | 28.6% | 11 / 20 | 20 / 25 | 2M | 4M |
| Q1 2025 | 75 | 31M | 31.1% | 9 / 16 | 24 / 7 | 1M | 1M |
| Q4 2024 | 75 | 32M | 31.5% | 13 / 26 | 19 / 16 | 6M | 10M |
| Q3 2024 | 78 | 36M | 36.2% | 15 / 29 | 18 / 9 | 5M | 1M |
| Q2 2024 | 74 | 34M | 34.1% | 23 / 28 | 17 / 18 | 6M | 4M |
| Q1 2024 | 70 | 32M | 31.6% | 26 / 25 | 10 / 13 | 5M | 3M |
| Q4 2023 | 57 | 29M | 29.1% | 25 / 14 | 10 / 8 | 10M | 0M |
| Q3 2023 | 41 | 20M | 19.8% | 1 / 6 | 19 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
92 funds held STTK in Q2 2026, 30% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of STTK | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Value Fund, Inc. | 3,565,344 | 3.55% | $24.74M | 0.23% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3,114,735 | 3.10% | $21.62M | 0.23% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,366,616 | 2.36% | $16.42M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,986,099 | 1.98% | $13.78M | 0.12% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 1,677,742 | 1.67% | $11.64M | 0.23% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,538,564 | 1.53% | $10.68M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 768,222 | 0.77% | $5.33M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 671,918 | 0.67% | $4.75M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 501,709 | 0.50% | $3.48M | 0.02% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 391,662 | 0.39% | $2.33M | 0.04% | May 31, 2026 |
| Vanguard Explorer Fund | 319,591 | 0.32% | $2.26M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 284,317 | 0.28% | $1.69M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 206,111 | 0.21% | $1.43M | 0.09% | Jun 30, 2026 |
| Small Cap Value Portfolio | 203,628 | 0.20% | $1.41M | 0.21% | Jun 30, 2026 |
| North Square Dynamic Small Cap Fund | 200,532 | 0.20% | $1.19M | 0.15% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Taylor Schreiber | Chief Executive Officer, Director | 2,732,972 | 2.72% | May 13, 2026 |
| Abhinav A. Shukla | Chief Technical Officer | 98,533 | 0.10% | Jul 7, 2026 |
| Arundathy N. Pandite | Chief Medical Officer | 136,219 | 0.14% | Jul 2, 2026 |
| Stephen Stout | See Remarks | 93,366 | 0.09% | May 18, 2026 |
| Andrew R. Neill | Chief Financial Officer | 292,251 | 0.29% | May 14, 2026 |
| Casi DeYoung | Chief Business Officer | 73,480 | 0.07% | Jan 27, 2026 |
| Genesis GP LLC OrbiMed | Director | 1,051,021 | 1.05% | Jun 15, 2026 |
| Advisors Llc Orbimed | Director | 5,255,106 | 5.24% | Jun 15, 2026 |
| Mona Ashiya | Director | 5,255,106 | 5.24% | Jun 15, 2026 |
| Capital GP IX LLC OrbiMed | Director | 1,051,021 | 1.05% | Jun 15, 2026 |
| Clay B. Siegall | Director | 318,608 | 0.32% | Jun 11, 2026 |
| Helen M. Boudreau | Director | – | – | Jun 2, 2026 |
| George Golumbeski | Director | 54,613 | 0.05% | Jun 2, 2026 |
| Daniel G. Baker | Director | – | – | Jun 2, 2026 |
| Neil W. Gibson | Director | 52,745 | 0.05% | Jun 2, 2026 |
| Jeremy Green | Director, 10% owner | 5,406,353 | 5.39% | Aug 26, 2025 |
| Redmile Group, LLC | Director, 10% owner | 5,615,489 | 5.60% | Aug 26, 2025 |
| Tyler Brous | Director | 238,088 | 0.24% | Jul 16, 2025 |
| Carrie Brownstein | Director | – | – | Jul 16, 2025 |
| Michael Stewart Lee | Director | – | – | Jul 16, 2025 |
| Amy Kate Sasser | Director | – | – | Jul 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Abhinav A. Shukla Chief Technical Officer | Jul 6, 2026 | Option exercise | +12,153 | $3.57 | $43.39K | 98,533 |
| Abhinav A. Shukla Chief Technical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −410 | $7.01 | $2.87K | 86,380 |
| Abhinav A. Shukla Chief Technical Officer | Jul 2, 2026 | Option exercise | +410 | $3.57 | $1.46K | 86,790 |
| Abhinav A. Shukla Chief Technical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −100 | $7.07 | $707 | 86,380 |
| Abhinav A. Shukla Chief Technical Officer | Jul 1, 2026 | Option exercise | +100 | $3.57 | $357 | 86,480 |
| Arundathy N. Pandite Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −30,000 | $7.01 | $210.30K | 136,219 |
| Abhinav A. Shukla Chief Technical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −23,365 | $7.08 | $165.42K | 86,380 |
| Abhinav A. Shukla Chief Technical Officer | Jun 30, 2026 | Option exercise | +23,365 | $3.57 | $83.41K | 109,745 |
| Clay B. Siegall Director | Jun 9, 2026 | Buy | +62,500 | $4.00 | $250.00K | 318,608 |
| Clay B. Siegall Director | May 22, 2026 | Award | +128,054 | $1.08 | $138.30K | 256,108 |
| Abhinav A. Shukla Chief Technical Officer | May 21, 2026 | Award | +5,122 | $1.08 | $5.53K | 86,380 |
| Stephen Stout See Remarks | May 15, 2026 | Award | +12,805 | $1.08 | $13.83K | 93,366 |
| Abhinav A. Shukla Chief Technical Officer | May 12, 2026 | Option exercise | +2,032 | $3.57 | $7.25K | 83,290 |
| Abhinav A. Shukla Chief Technical Officer | May 12, 2026 | Sale(10b5-1 plan) | −2,032 | $7.01 | $14.24K | 81,258 |
| Andrew R. Neill Chief Financial Officer | May 12, 2026 | Award | +64,027 | $1.08 | $69.15K | 292,251 |
| Arundathy N. Pandite Chief Medical Officer | May 12, 2026 | Sale(10b5-1 plan) | −30,000 | $6.61 | $198.30K | 166,219 |
| Taylor Schreiber Chief Executive Officer, Director | May 12, 2026 | Award | +25,610 | $1.08 | $27.66K | 122,222 |
| Stephen Stout See Remarks | May 10, 2026 | Tax withholding | −968 | $6.85 | $6.63K | 80,561 |
| Casi DeYoung Chief Business Officer | Jan 25, 2026 | Tax withholding | −2,286 | $4.15 | $9.49K | 73,480 |
| Andrew R. Neill Chief Financial Officer | Jan 25, 2026 | Tax withholding | −2,589 | $4.15 | $10.74K | 228,224 |
| Stephen Stout See Remarks | Jan 25, 2026 | Tax withholding | −593 | $4.15 | $2.46K | 81,529 |
| Arundathy N. Pandite Chief Medical Officer | Jan 25, 2026 | Tax withholding | −3,195 | $4.15 | $13.26K | 196,219 |
| Arundathy N. Pandite Chief Medical Officer | Jan 10, 2026 | Tax withholding | −6,851 | $4.75 | $32.54K | 199,414 |
| Casi DeYoung Chief Business Officer | Jan 10, 2026 | Tax withholding | −5,699 | $4.75 | $27.07K | 75,766 |
| Andrew R. Neill Chief Financial Officer | Jan 10, 2026 | Tax withholding | −6,660 | $4.75 | $31.64K | 230,813 |
| Stephen Stout See Remarks | Jan 10, 2026 | Tax withholding | −4,153 | $4.75 | $19.73K | 82,122 |
| Mona Ashiya Director | Aug 25, 2025 | Buy | +5,255,106 | $0.87 | $4.57M | 5,255,106 |
| Mona Ashiya Director | Aug 25, 2025 | Buy | +1,051,021 | $0.87 | $914.39K | 1,051,021 |
| Capital GP IX LLC OrbiMed Director | Aug 25, 2025 | Buy | +1,051,021 | $0.87 | $914.39K | 1,051,021 |
| Capital GP IX LLC OrbiMed Director | Aug 25, 2025 | Buy | +5,255,106 | $0.87 | $4.57M | 5,255,106 |
| Abhinav A. Shukla Chief Technical Officer | Aug 25, 2025 | Award | +5,122 | $0.87 | $4.46K | 81,258 |
| Andrew R. Neill Chief Financial Officer | Aug 25, 2025 | Award | +64,027 | $0.87 | $55.70K | 237,473 |
| Clay B. Siegall Director | Aug 25, 2025 | Award | +128,054 | $0.87 | $111.41K | 128,054 |
| Taylor Schreiber Chief Executive Officer, Director | Aug 25, 2025 | Award | +25,610 | $0.87 | $22.28K | 96,612 |
| Stephen Stout See Remarks | Aug 25, 2025 | Award | +12,805 | $0.87 | $11.14K | 86,275 |
| Abhinav A. Shukla Chief Technical Officer | Jan 25, 2025 | Tax withholding | −2,261 | $1.16 | $2.62K | 73,536 |
| Arundathy N. Pandite Chief Medical Officer | Jan 25, 2025 | Tax withholding | −3,211 | $1.16 | $3.72K | 206,265 |
| Casi DeYoung Chief Business Officer | Jan 25, 2025 | Tax withholding | −2,297 | $1.16 | $2.66K | 81,465 |
| Abhinav A. Shukla Chief Technical Officer | Jan 10, 2025 | Tax withholding | −4,830 | $1.19 | $5.75K | 74,597 |
| Casi DeYoung Chief Business Officer | Jan 10, 2025 | Tax withholding | −5,727 | $1.19 | $6.82K | 83,762 |
| Arundathy N. Pandite Chief Medical Officer | Jan 10, 2025 | Tax withholding | −6,884 | $1.19 | $8.19K | 209,476 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Sale | −133,371 | $1.25 | $166.71K | 5,406,353 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Other | +1,026,888 | $1.25 | $1.28M | 5,539,724 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Other | −1,026,888 | $1.25 | $1.28M | 4,512,836 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Buy | +133,371 | $1.25 | $166.71K | 5,539,724 |
| Taylor Schreiber Chief Executive Officer, Director | Oct 7, 2024 | Buy | +36,500 | $1.21 | $44.17K | 71,002 |
| Tyler Brous Director | Jun 28, 2024 | Buy | +3,000 | $3.90 | $11.70K | 238,088 |
| Tyler Brous Director | Jun 27, 2024 | Buy | +5,416 | $3.89 | $21.07K | 235,088 |
| Taylor Schreiber Chief Executive Officer, Director | Jun 26, 2024 | Buy | +14,400 | $3.47 | $49.97K | 34,502 |
| Taylor Schreiber Chief Executive Officer, Director | Jun 4, 2024 | Option exercise | +3,050 | $3.57 | $10.89K | 20,102 |
| Stephen Stout See Remarks | May 10, 2024 | Tax withholding | −967 | $10.42 | $10.08K | 73,470 |
| Redmile Group, LLC Director, 10% owner | Mar 28, 2024 | Other | −4,425 | – | – | 5,615,489 |
| Stephen Stout See Remarks | Mar 6, 2024 | Option exercise | +6,459 | $3.57 | $23.06K | 85,791 |
| Stephen Stout See Remarks | Mar 6, 2024 | Sale(10b5-1 plan) | −6,459 | $10.53 | $68.01K | 79,332 |
| Stephen Stout See Remarks | Mar 6, 2024 | Sale(10b5-1 plan) | −4,895 | $10.53 | $51.54K | 74,437 |
| Stephen Stout See Remarks | Mar 6, 2024 | Sale(10b5-1 plan) | −4,650 | $10.53 | $48.96K | 79,332 |
| Stephen Stout See Remarks | Mar 6, 2024 | Option exercise | +4,650 | $3.51 | $16.32K | 83,982 |
| Arundathy N. Pandite Chief Medical Officer | Jan 30, 2024 | Tax withholding | −2,920 | $9.99 | $29.17K | 216,360 |
| Stephen Stout See Remarks | Jan 30, 2024 | Tax withholding | −593 | $9.99 | $5.92K | 79,332 |
| Casi DeYoung Chief Business Officer | Jan 30, 2024 | Tax withholding | −2,008 | $9.99 | $20.06K | 89,489 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
14.11%
11M shares short
Days to cover
12.0
At 1M shares a day
Change since last report
+2.9%
From 10M shares
Short volume, 20 days
60.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Shattuck Labs's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,501 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Abhinav A. Shukla Officer | Jul 2, 2026 | 410 | $2.87K | Jul 2, 2026 | Stock Option Exercise |
| Abhinav A. Shukla Officer | Jul 1, 2026 | 100 | $707 | Jul 1, 2026 | Stock Option Exercise |
| Abhinav A. Shukla Officer | Jun 30, 2026 | 23,365 | $165.47K | Jun 30, 2026 | Stock Option Exercise |
| Arunthathy Pandite Officer | May 12, 2026 | 60,000 | $421.20K | May 12, 2026 | Restricted Stock Awards |
| Abhinav A. Shukla Officer | May 12, 2026 | 2,032 | $14.24K | May 12, 2026 | Option Granted - 01/25/2023 |
| Redmile Group, LLC Director, 10% Stockholder | Dec 4, 2024 | 133,371 | $150.71K | Dec 4, 2024 | Open Market Purchases or Purchases in Public Offering |
| Stephen Stout Officer | Mar 6, 2024 | 16,004 | $168.52K | Mar 6, 2024 | Restricted Stock |
| Andrew R. Neill Officer | Jan 10, 2024 | 25,000 | $250.00K | Jan 10, 2024 | Option Exercise |
See a number that looks wrong?